Clinical Trial 49857

Middletown, NJ 07748


Summary:

<b>Breast Cancer - Multiple Locations in the US</b>

A new clinical research study for people with ER-positive, HER2-negative breast cancer

PersevERA is a phase 3 clinical study evaluating an investigational oral hormone therapy for people diagnosed with ER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

PersevERA at a Glance

  • Participants: Eligible adults with locally advanced or metastatic breast cancer
  • Duration: Approximately 82 months
  • Administration: Taken orally during three 28-day treatment cycles

Who may be eligible?

Participants in the persevERA Study must meet the following eligibility criteria:*
  • Be 18 years of age or older
  • Be diagnosed with ER-positive, HER2-negative locally advanced or metastatic breast cancer
  • Have not received any prior treatment with a SERD (e.g., fulvestrant)

*Additional criteria apply.


Available At:

To learn more and find out if you may be eligible, please CLICK HERE.

To view an updated list of participating research sites click
here.

 


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.